📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-27 19:28
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
51 announcements match the current filters (relevance ≥ 5).
CARE Upgrades Hester Biosciences' Long-Term Bank Facilities Rating to 'BBB+; Stable' from 'BBB'
CARE Ratings has upgraded Hester Biosciences' credit ratings across bank facilities totaling ₹113.67 crore. Long-term facilities of ₹48.45 crore (reduced from ₹66.25 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Long-term / short-term facilities (₹65.00 crore) and short-term facilities (₹0.22 crore) were upgraded to CARE BBB+ / CARE A2 and CARE A2, respectively, driven by operational and financial performance in FY26 and Q1FY27.
Confidence: HIGH
What changedCARE Ratings upgraded Hester Biosciences' long-term bank facilities rating to 'CARE BBB+; Stable' from 'CARE BBB; Stable' and short-term rating to 'CARE A2' from 'CARE A3+'.
Why it mattersThe rating upgrade signals an improving financial and liquidity profile post-FY26 earnings recovery, potentially lowering future interest costs and improving debt terms.
Total rated bank facilities: ₹113.67 croreRated facilities vs TTM revenue: ~34.9%Long-term facilities rated: ₹48.45 croreCash credit limit: ₹60.00 croreOutstanding foreign currency loan: $4.00 Mn (₹37.87 crore)
📅 Short termPositive sentiment driver reflecting strengthening creditworthiness and sound balance sheet position.
📈 Long termImproves financial flexibility and lowers risk premium for prospective debt-funded expansions or working capital scale-up.
⚠ Risk flags
- Forex exposure risk on outstanding $4.00 million SBI term loan
- Dependency on lumpy institutional tender business in export and regional markets
Key Highlights
Long-term bank facility rating upgraded to CARE BBB+; Stable from CARE BBB; Stable across ₹48.45 crore.
Short-term facility rating upgraded to CARE A2 from CARE A3+ across fund and non-fund based limits.
Total bank facilities under rating stand at ₹113.67 crore, representing ~34.9% of FY26 TTM revenue.
Outstanding long-term debt as on June 30, 2026 includes ₹10.58 crore in INR term loans and ₹37.87 crore ($4.00 million) in foreign currency term loans.
👀 What to Watch
Track whether the rating upgrade translates into lower borrowing costs on working capital lines and monitor operating cash flow trends in upcoming quarterly results.
Ester Industries Q1 FY27 Concall: Film Revenue Up 38% YoY, Specialty Polymer EBIT Margin at 45.3%
Ester Industries released the transcript of its Q1 FY27 earnings call, highlighting an improving operating environment for the BOPET film industry following the moderation of US punitive tariffs. Consolidated film revenues grew ~38% YoY to INR 399.5 Cr on 22,120 MT volume, with capacity utilization rising to 84%. Value-Added Specialty (VAS) films grew 23% YoY to 6,368 MT, representing 29% of total film volume. Specialty Polymers revenue dropped to INR 32.7 Cr due to demand pressure in one product, but EBIT margins expanded sharply to 45.3% from 31.7% YoY due to an improved product mix.
Confidence: HIGH
What changedEster Industries published the detailed transcript of its Q1 FY27 earnings conference call held on August 18, 2026.
Why it mattersProvides granularity on margin recovery, the benefit of reversed US import tariffs, and structural progress toward high-margin specialty films and recycled PET products.
Film Segment Revenue: INR 399.5 CrVAS Share of Film Volume: 29%Specialty Polymers EBIT Margin: 45.3%rPET Capacity: 30,000 MTPACommodity Film Spreads: INR 28 to INR 30
📅 Short termStable packaging spreads and increasing VAS share support operating profitability after multiple loss-making quarters in FY26.
📈 Long termStrategic shift to 50-60% VAS mix, expanded rPET capacity, and the ELITe JV could help structurally reduce commodity cycle vulnerability.
⚠ Risk flags
- Cyclicality in global BOPET demand-supply dynamics
- Raw material price volatility (PTA/MEG)
- Demand concentration risk in certain high-margin specialty polymer products
Key Highlights
Consolidated film segment revenue rose ~38% YoY to INR 399.5 Cr with EBIT margin around 10%
VAS film volume increased 23% YoY to 6,368 MT, contributing 29% to total film volumes (targeting 50-60% in 2-3 years)
Specialty Polymers EBIT margin expanded to 45.3% (from 31.7% in Q1 FY26) despite revenue declining to INR 32.7 Cr
Consolidated capacity utilization reached 84% in Q1 FY27, with management indicating Q2 utilization is tracking higher
Created 30,000 TPA recycled PET capacity to capitalize on Indian plastic waste management mandates
👀 What to Watch
Track the upcoming credit rating review completion by end-August 2026 and monitor sustainability of commodity film spreads (held at INR 28-30/kg) and ramp-up of the ELITe JV project.
₹18.6 Cr PAT Turnaround: Ester Industries Q1 FY27 EBITDA Doubles on Margin Expansion
Ester Industries reported a significant financial turnaround in Q1 FY27, with consolidated revenue growing 27.4% YoY to ₹441.9 crore. EBITDA more than doubled to ₹58.9 crore, driven by a 500 bps margin expansion to 13.3% as predatory pricing from China eased. The company returned to profitability with a PAT of ₹18.6 crore compared to a loss of ₹7.2 crore in the previous year. Notably, the ELITe JV project secured a multi-year offtake Letter of Intent (LoI) for 15,000 MTPA from a global sports brand, providing strong revenue visibility.
Confidence: HIGH
What changedThe company has transitioned from a loss-making period to significant profitability, supported by a recovery in the BOPET film market and a major offtake agreement for its upcoming recycling project.
Why it mattersThe turnaround indicates that the worst of the industry-wide pricing pressure from China may be over, and the high-margin Specialty Polymer and ELITe recycling segments are beginning to de-risk the earnings profile.
Q1 FY27 Revenue: ₹441.9 CrQ1 FY27 PAT: ₹18.6 CrEBITDA Margin: 13.3%ELITe Offtake Volume: 15,000 MTPAQ1 Revenue vs TTM Revenue: 34.3%
📅 Short termThe stock is likely to react positively to the sharp PAT turnaround and the validation of the ELITe project through the global brand offtake agreement.
📈 Long termStructural shift towards value-added products and sustainable recycling (ELITe project) could lead to a re-rating if the company maintains double-digit margins across cycles.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Cyclicality of BOPET film margins
- Raw material price volatility (PTA/MEG)
- Execution risk of the ELITe JV project
Key Highlights
Consolidated Total Income rose 27.4% YoY to ₹441.9 crore, representing ~34% of TTM revenue in a single quarter.
EBITDA surged 103.4% YoY to ₹58.9 crore with margins expanding from 8.3% to 13.3%.
PAT turned positive at ₹18.6 crore against a loss of ₹7.2 crore in Q1 FY26.
ELITe JV secured a multi-year LoI for 15,000 MTPA offtake from a leading global sports and athletic brand.
Polyester Films revenue grew 37.7% YoY to ₹399.5 crore, while Specialty Polymer EBIT margins improved to 45.3%.
👀 What to Watch
Monitor the commercialization timeline of the ELITe project in Gujarat and the sustainability of the 13.3% EBITDA margin given the historical cyclicality of the BOPET film industry.
103.4% EBITDA Growth and 15,000 MT Multi-Year LOI for ELITe JV
Ester Industries reported a sharp financial turnaround in Q1 FY27, with consolidated revenue growing 27.4% YoY to ₹441.9 Cr and PAT turning positive at ₹18.6 Cr (vs. a loss of ₹7.2 Cr). EBITDA more than doubled to ₹58.9 Cr as margins expanded by 500 bps to 13.3%, aided by reduced predatory pricing from China and a better product mix. Significantly, the ELITe JV (50:50 with Loop Industries) secured a multi-year Letter of Intent (LOI) from a global sports brand for up to 15,000 MT per year of recycled PET resin. This LOI provides high revenue visibility for the upcoming Gujarat facility ahead of its commercial start-up.
Confidence: HIGH
What changedThe company has transitioned from a loss-making FY26 to a profitable Q1 FY27 and secured its first major global customer validation for the ELITe recycled PET project.
Why it mattersThe turnaround in the core film business combined with the de-risking of the ELITe JV through a large-scale LOI strengthens the company's cash flow outlook and validates its shift toward sustainable specialty products.
Q1 FY27 Consolidated Revenue: ₹441.9 CrEBITDA Margin Expansion: 500 bpsLOI Annual Volume: 15,000 MTQ1 PAT: ₹18.6 CrQ1 Revenue vs FY26 TTM Revenue: 34.3%
📅 Short termThe stock is likely to react positively to the strong earnings turnaround and the material LOI announcement which provides future growth certainty.
📈 Long termThe ELITe JV represents a structural shift toward the circular economy; successful execution of the 15,000 MT LOI could significantly re-rate the company's valuation as it moves away from commodity films.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the upcoming Gujarat facility
- Volatility in raw material costs (PTA/MEG)
- Potential reversal of Chinese 'anti-involution' pricing policies
Key Highlights
Consolidated EBITDA surged 103.4% YoY to ₹58.9 Cr with margins improving to 13.3%.
PAT turned positive at ₹18.6 Cr for Q1 FY27, compared to a loss of ₹7.2 Cr in Q1 FY26.
ELITe JV secured a multi-year LOI for up to 15,000 MT per year of Loop™ PET Fiber Grade resin.
Polyester Film revenue grew 37% YoY to ₹399.5 Cr, supported by 84% capacity utilization.
Value-Added & Specialty (VAS) volumes in the film segment grew 23% YoY to 6,368 MT.
👀 What to Watch
Monitor the execution and commissioning timeline of the ELITe Gujarat facility, as a significant portion of its capacity is now pre-committed. Investors should also track if the 13.3% EBITDA margin is sustainable or if it fluctuates with global PTA/MEG prices.
₹18.6 Cr PAT: Ester Industries Turns Profitable in Q1 FY27 as EBITDA Doubles
Ester Industries reported a strong financial turnaround in Q1 FY27, posting a consolidated PAT of ₹18.6 Cr against a loss of ₹7.2 Cr in Q1 FY26. Revenue grew 27.4% YoY to ₹441.9 Cr, primarily driven by a 37% surge in Polyester Film revenue. EBITDA margins expanded significantly by 500 bps to 13.3%, supported by a better product mix and reduced predatory pricing from China. Notably, the ELITe JV project secured a multi-year offtake Letter of Intent (LoI) for 15,000 MTPA from a global sports brand, providing high revenue visibility for upcoming capacity.
Confidence: HIGH
What changedThe company has transitioned from a loss-making period to significant profitability, driven by operational efficiency and a recovery in the BOPET film industry.
Why it mattersThe turnaround validates Ester's shift toward high-margin specialty products and sustainable recycled polyester, while the 15,000 MTPA LoI de-risks the upcoming ELITe project capacity.
Q1 FY27 Consolidated Revenue: ₹441.9 CrQ1 Revenue vs TTM Revenue: ~34.3%EBITDA Margin Expansion: 500 bpsELITe Project Offtake LoI: 15,000 MTPAVAS Volume Growth: 23% YoY
📅 Short termThe stock is likely to react positively to the sharp margin expansion and the return to net profitability after several quarters of losses.
📈 Long termThe structural shift toward the ELITe JV and recycled PET (rPET) could lead to a re-rating if the company successfully executes its sustainable polyester strategy and maintains high specialty margins.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Cyclicality of the BOPET film industry
- Volatility in raw material costs (PTA/MEG)
- Potential re-emergence of predatory pricing from international markets
Key Highlights
Consolidated EBITDA surged 103.4% YoY to ₹58.9 Cr, with margins improving from 8.3% to 13.3%.
Polyester Film revenue grew 37% YoY to ₹399.5 Cr, supported by a 23% growth in Value-Added & Specialty (VAS) volumes.
ELITe project secured a multi-year LoI for up to 15,000 MT per annum of Loop™ PET Fiber Grade resin.
Consolidated capacity utilization increased to 84% in Q1 FY27 from 82% in the previous year.
Specialty Polymers segment EBIT margin improved to 45.3% despite a 32% decline in segment revenue.
👀 What to Watch
Watch for the commercial start-up timeline of the ELITe Gujarat facility and the sustainability of the 13.3% EBITDA margin, which is currently benefiting from favorable industry shifts and reduced Chinese competition.
Ester Industries sets Sep 17 as Record Date for Rs 0.25 dividend; raises Rs 106 Cr via warrants
Ester Industries has fixed September 17, 2026, as the record date for a final dividend of Rs 0.25 per share for FY26. The company also approved Q1 FY27 results and confirmed its 40th AGM for September 24, 2026. Notably, the company completed a warrant conversion during the quarter, raising Rs 105.99 crore by issuing 67.08 lakh shares at Rs 158 each. This capital infusion represents approximately 10.4% of the current market capitalization, providing liquidity despite a TTM net loss of Rs 31 crore.
Confidence: HIGH
What changedThe company has finalized the timeline for its annual dividend payout and significantly increased its equity base and cash reserves through warrant conversions.
Why it mattersThe Rs 106 crore fundraise at Rs 158 per share (a premium to the current market price of Rs 104.5) strengthens the balance sheet, which is vital given the company's recent loss-making quarters and debt of Rs 334 crore.
Dividend per share: Rs 0.25Record Date: 17-Sep-2026Warrant Conversion Price: Rs 158Capital Raised via Warrants: Rs 105.99 crFundraise vs Market Cap: ~10.4%
📅 Short termThe stock may see limited movement as the dividend yield is low (~0.24%), but the successful capital raise at a premium provides a positive sentiment floor.
📈 Long termThe structural focus on Specialty Polymers (39% YoY growth) and the ELITe JV project are the primary long-term value drivers, while the current packaging film segment remains under pressure from global pricing.
⚠ Risk flags
- TTM net loss of Rs 31 crore
- Volatile raw material costs (PTA/MEG)
- Predatory pricing in the domestic BOPET film market
Key Highlights
Final dividend of Rs 0.25 per equity share recommended for the financial year 2025-26.
Record date for dividend eligibility and AGM voting fixed as September 17, 2026.
Raised Rs 105.99 crore through the conversion of 67,08,851 warrants at a price of Rs 158 per share.
Paid-up equity share capital increased to Rs 52.15 crore, comprising 10.43 crore shares as of June 30, 2026.
Dividend payment, if approved at the AGM, will be completed by October 24, 2026.
👀 What to Watch
Investors should monitor the AGM on September 24 for updates on the ELITe JV project and the ramp-up of the new Hyderabad extruder, which are critical for reversing the current TTM losses.
Ester Industries Allots Rs 106 Cr via Warrants at 51% Premium; Reports Q1 FY27 Results
Ester Industries reported a turnaround in its Specialty Polymers segment for Q1 FY27, contributing Rs 23.53 Cr to segment profits compared to a loss in the same quarter last year. The company successfully converted 67.08 lakh warrants into equity at Rs 158 per share, a significant premium to the current market price of Rs 104.5, raising Rs 105.99 Cr. A final dividend of Rs 0.25 per share has been confirmed with a record date of September 17, 2026. The equity infusion strengthens the balance sheet, representing approximately 10.4% of the current market capitalization.
Confidence: HIGH
What changedThe company has transitioned from a loss-making TTM period to a profitable Q1 FY27, supported by a significant capital infusion at a high premium.
Why it mattersThe warrant conversion at Rs 158 (vs current price of Rs 104.5) signals strong promoter/investor confidence and provides liquidity for the ELITe JV project, while the Specialty Polymer segment's recovery addresses previous margin concerns.
Warrant Conversion Value: Rs 105.99 CrConversion vs Market Cap: 10.4%Warrant Issue Price: Rs 158Specialty Polymer Segment Profit (Q1): Rs 23.53 CrDividend per Share: Rs 0.25
📅 Short termThe stock may see positive sentiment due to the earnings turnaround and the high-premium warrant conversion, which validates internal valuation expectations.
📈 Long termThe structural shift toward Specialty Polymers and sustainable polyester through the ELITe JV remains the primary long-term value driver for the company.
⚠ Risk flags
- Predatory pricing in the domestic film segment
- Volatility in raw material costs (PTA/MEG)
- Forex fluctuation risks
Key Highlights
Allotted 67,08,851 equity shares at Rs 158 per share, totaling Rs 105.99 Cr via warrant conversion
Specialty Polymers segment profit rose to Rs 23.53 Cr in Q1 FY27 from a loss of Rs 3.81 Cr YoY
Polyester chips and film segment contributed Rs 13.33 Cr to segment results for the quarter
Paid-up equity capital increased to Rs 52.15 Cr following the warrant conversion
Record date for Rs 0.25 per share dividend fixed for September 17, 2026
👀 What to Watch
Investors should monitor the margin sustainability in the Specialty Polymers segment and the utilization levels of the new Telangana plant, as these are key to maintaining the current earnings turnaround.
88% Standalone PAT Growth in Q1 FY27; Gates Foundation Waives $7M Debt for Africa
Hester Biosciences reported a strong standalone performance for Q1 FY27 with 14% revenue growth and an 88% surge in PAT, driven by a 48% growth in the Poultry Healthcare division. Gross margins expanded significantly from 69% to 78% due to a favorable product mix and operational efficiencies. A major highlight is the restructuring of the Gates Foundation loan for Hester Africa, reducing the debt from $12 million to $5 million and making it interest-free. Despite standalone strength, consolidated revenue declined 8% due to lumpy institutional orders in Nepal and Africa.
Confidence: HIGH
What changedHester has successfully improved its standalone margin profile through a better product mix and secured a significant debt waiver that de-risks its international balance sheet.
Why it mattersThe 900 bps margin expansion and debt reduction significantly improve the company's cash flow outlook and reduce the drag from the African subsidiary on consolidated earnings.
Standalone PAT Growth (YoY): 88%Gross Margin: 78%Debt Reduction (Africa): $7 millionIndia Plant Capex: ₹182 CrCapex vs Net Worth: 47.1%Poultry Division Growth: 48%
📅 Short termThe market is likely to react positively to the sharp margin expansion and the one-time exceptional gain from the debt waiver.
📈 Long termThe shift from tender-based business to private commercial markets and the expansion of the biological pipeline are structural positives for long-term valuation.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Lumpy revenue from government tenders in the Animal Healthcare division
- Geopolitical and operating challenges in African markets
Key Highlights
Standalone PAT increased by 88% YoY, while EBITDA grew by 95% reflecting strong operating leverage.
Gross margins improved to 78% from 69% in the previous year's corresponding quarter.
Poultry Healthcare division recorded 48% growth, supported by new health products and deeper market penetration.
Gates Foundation reduced Hester Africa's outstanding loan by $7 million (from $12M to $5M) and waived accrued interest.
Ongoing ₹182 Cr investment in the India plant is on track to be operational by March 2026.
👀 What to Watch
Watch for the operationalization of the ₹182 Cr India plant expansion by March 2026 and the progress toward the FY28 breakeven target for African operations.
Q1 FY27: Standalone PAT up 88% to ₹14.7 Cr; ₹85.3 Cr Exceptional Gain from Debt Reduction
Hester Biosciences reported a strong standalone performance for Q1 FY27 with revenue growing 14% to ₹72.66 Cr and PAT rising 88% to ₹14.71 Cr. The Poultry Healthcare division was the primary driver, growing 48% YoY, while the Animal Healthcare division saw a 50% decline due to government tender delays. A massive consolidated PAT surge of 459% was recorded, primarily due to an ₹85.35 Cr exceptional gain following a debt reduction agreement with the Gates Foundation for Hester Africa. Standalone EBITDA margins expanded significantly to 36% from 21% in the previous year.
Confidence: HIGH
What changedHester achieved a significant operational turnaround in its standalone poultry business and secured a major debt haircut for its African subsidiary, substantially de-risking its consolidated balance sheet.
Why it mattersThe debt reduction at Hester Africa removes a significant financial overhang, while the 48% growth in poultry vaccines demonstrates successful market penetration in the private commercial segment, reducing reliance on volatile government tenders.
Standalone Revenue (Q1): ₹72.66 CrStandalone PAT (Q1): ₹14.71 CrExceptional Gain (Consolidated): ₹85.35 CrExceptional Gain vs TTM Revenue: 26.18%Poultry Healthcare Growth: 48%Standalone EBITDA Margin: 36%
📅 Short termThe stock is likely to react positively to the strong standalone margin expansion and the massive bottom-line boost from the debt restructuring, despite the weakness in the animal healthcare segment.
📈 Long termThe structural shift toward a higher-margin private product mix and the de-leveraging of the African unit position the company for more stable earnings growth over the next 2-3 years.
⚠ Risk flags
- High volatility in Animal Healthcare revenue due to 50% dependency on government tender timing
- Continued variability in institutional orders from Nepal and Africa operations
Key Highlights
Standalone Revenue increased 14% YoY to ₹72.66 Cr, led by a 48% surge in Poultry Healthcare sales.
Consolidated PAT reached ₹96.73 Cr, boosted by an ₹85.35 Cr exceptional gain from restructuring a $12 million loan to $5 million.
Standalone Gross Profit margins improved to 78% from 69% due to a favorable product mix and operational efficiencies.
Animal Healthcare division revenue fell 50% to ₹10.84 Cr, attributed to the timing of government-led immunization programs.
Hester Africa's outstanding loan from the Gates Foundation was reduced by $7 million and made interest-free.
👀 What to Watch
Investors should monitor the recovery of the Animal Healthcare tender business in upcoming quarters and the progress of the ₹182 Cr India plant expansion. The sustainability of the 78% gross margin in the absence of lumpy government contracts is a key metric to watch.
₹85.35 Cr Exceptional Gain Drives Hester Bio Q1 PAT to ₹96.73 Cr; Debt Reduced by $7M
Hester Biosciences reported a consolidated PAT of ₹96.73 cr for Q1 FY27, a significant jump from ₹17.30 cr YoY, primarily due to an ₹85.35 cr exceptional gain. This gain resulted from a loan restructuring with the Gates Foundation, which reduced the principal from $12 million to $5 million and waived all interest. While consolidated revenue from operations declined 8.2% YoY to ₹77.24 cr, the Poultry Healthcare segment showed robust growth of 47.5% YoY. However, the Animal Healthcare segment saw a sharp 64% decline in revenue, impacting overall top-line performance.
Confidence: HIGH
What changedThe company successfully restructured its debt with the Gates Foundation, leading to a $7 million principal reduction and interest waiver, while the business mix shifted heavily toward Poultry Healthcare.
Why it mattersThe debt reduction significantly strengthens the balance sheet and reduces future interest costs. However, the volatility in the Animal Healthcare segment highlights the company's ongoing challenge with lumpy institutional and tender-based orders.
Exceptional Gain: ₹85.35 crConsolidated Revenue (Q1): ₹77.24 crPoultry Segment Revenue: ₹62.13 crAnimal Segment Revenue: ₹15.11 crLoan Principal Reduction: $7 millionExceptional Gain vs TTM PAT: ~150%
📅 Short termThe stock may react positively to the massive headline profit and the substantial debt reduction, which improves the net worth significantly.
📈 Long termThe balance sheet cleanup is a structural positive, but long-term value depends on stabilizing the Animal Healthcare segment and successfully scaling the Africa operations to breakeven.
⚠ Risk flags
- High volatility in Animal Healthcare segment revenue
- Dependency on institutional/tender-based orders
- Segment loss in Animal Healthcare (₹4.18 cr loss at consolidated level)
Key Highlights
Exceptional gain of ₹85.35 cr recognized following a loan waiver and restructuring with the Gates Foundation (USA).
Consolidated revenue from operations stood at ₹77.24 cr, down 8.2% from ₹84.11 cr in Q1 FY26.
Poultry Healthcare segment revenue grew 47.5% YoY to ₹62.13 cr, up from ₹42.12 cr.
Animal Healthcare segment revenue plummeted 64% YoY to ₹15.11 cr from ₹41.98 cr.
Consolidated EPS for the quarter reached ₹113.71, compared to ₹20.33 in the same quarter last year.
👀 What to Watch
Investors should focus on the sustainability of the Poultry segment's growth and the reasons behind the sharp decline in Animal Healthcare. Watch for the operationalization of the BSL-3 and Fill-Finish facilities, which are currently listed as unallocated assets.
Hester Biosciences Sets July 14 as Record Date for INR 11 Per Share Final Dividend
Hester Biosciences Limited has fixed July 14, 2026, as the record date to determine shareholder eligibility for a final dividend of INR 11 per equity share for the financial year. This dividend represents a 110% payout on the face value of INR 10 per share. The distribution is subject to shareholder approval at the company's 39th Annual General Meeting. The record date also serves as the cutoff for determining members entitled to participate in e-voting for the AGM.
Key Highlights
Record date for dividend and AGM e-voting fixed for July 14, 2026.
Proposed final dividend of INR 11 per equity share (110% of face value).
Face value of the company's equity shares is INR 10 each.
Dividend payout is subject to approval at the 39th Annual General Meeting and applicable tax deductions.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 14 record date. Monitor the 39th AGM outcomes for final dividend declaration and payment timelines.
Hester Biosciences FY26 Consolidated PAT Surges 99% to ₹574.8M; AGM Set for July 21
Hester Biosciences reported a robust financial performance for FY 2025-26, with consolidated profit after tax (PAT) jumping 99% to ₹574.84 million despite a modest 7% revenue growth to ₹3,325.99 million. The company achieved significant margin expansion, with standalone EBITDA rising 56% to ₹871.03 million, driven by a favorable product mix and cost discipline. Key operational milestones include the commercialization of the H9N2 Avian Influenza vaccine and the repurposing of the BSL-3 facility for veterinary use. The company has scheduled its 39th AGM for July 21, 2026, and confirmed a dividend payout ratio of 18%.
Key Highlights
Consolidated PAT grew by 99% YoY to ₹574.84 million, while Standalone PAT rose 64% to ₹521 million.
Poultry Healthcare division recorded a strong 24% growth, supported by the launch of the H9N2 Avian Influenza vaccine.
Standalone EBITDA increased by 56% to ₹871.03 million, reflecting improved operational efficiencies.
The company capitalized its Fill-Finish and BSL-3 facilities, enhancing manufacturing scale-up capabilities.
Final dividend payment is scheduled on or after July 28, 2026, for shareholders as of the July 14 cut-off date.
👀 What to Watch
Investors should note the significant improvement in profitability and margins, suggesting successful cost management and a shift toward higher-margin products. The stock warrants a positive outlook given the successful commercialization of new vaccines and the operational readiness of advanced BSL-3 facilities.
Ester Industries Shareholders Approve Chairman Re-designation and Director Remuneration Revision
Ester Industries Limited has successfully passed two key resolutions via postal ballot with overwhelming shareholder support. Shareholders approved the re-designation of Mr. Arvind Singhania from Managing Director to Non-Executive, Non-Independent Chairman with 99.83% of votes in favor. Additionally, a special resolution to revise the remuneration of Whole-time Director Mr. Ayush Vardhan Singhania was approved with 99.30% support. These changes reflect a shift in the company's executive leadership structure and compensation policies.
Key Highlights
Resolution to re-designate Mr. Arvind Singhania as Non-Executive Chairman passed with 99.83% majority of valid votes cast.
Special resolution for revising remuneration of Mr. Ayush Vardhan Singhania approved with 99.30% votes in favor.
A total of 8,220,819 valid votes were polled for the first resolution, representing approximately 8.42% of total outstanding shares.
Promoter and interested party votes totaling 57,637,515 were excluded/treated as invalid for the voting process on these specific resolutions.
The voting process was conducted via remote e-voting from April 24, 2026, to May 23, 2026.
👀 What to Watch
Investors should note the transition of the Chairman to a non-executive role, which may indicate a shift toward more professionalized day-to-day management. No immediate portfolio action is required as the resolutions received strong support from non-interested shareholders.
Ester Industries Q4 FY26: Film EBIT up 73%, rPET Revenue Surges 3.7x, Dividend Declared
Ester Industries reported a significant turnaround in Q4 FY26, with consolidated film segment EBIT rising 73% YoY to INR 42 crores as industry headwinds like Chinese dumping and US tariffs moderate. The recycled PET (rPET) business emerged as a major growth driver, with full-year revenue surging 3.7x to INR 59.3 crores. The company also strengthened its balance sheet by securing INR 165.25 crores through share warrants and proposed a dividend of INR 0.25 per share. Management expects further margin expansion in FY27 following the expected formal notification of anti-dumping duties on BOPET films.
Key Highlights
Consolidated film segment EBIT grew 73% YoY to INR 42 crores in Q4 FY26, with margins expanding 440 bps to 13%
Recycled PET (rPET) revenue surged 3.7x YoY to INR 59.3 crores in FY26, supported by a 258% increase in volumes
Specialty Polymers segment reported FY26 revenue of INR 179.3 crores with high EBIT margins of 32.7%
Ester Filmtech subsidiary witnessed a turnaround with Q4 EBITDA rising 10x YoY to INR 18.6 crores
Successfully secured INR 165.25 crores against a share warrant issue of INR 175 crores to fund growth
👀 What to Watch
Investors should view the recovery in BOPET margins and the rapid scaling of the rPET business as strong positive indicators for FY27. Monitor the formal implementation of anti-dumping duties by the Ministry of Finance as a near-term catalyst for the stock.
Hester Bio Subsidiary Debt Reduced by USD 7M; Gates Foundation Waives Interest
Hester Biosciences Africa, a wholly-owned subsidiary of Hester India, has successfully renegotiated its loan terms with the Gates Foundation. The outstanding loan facility has been significantly reduced from USD 12 million to USD 5 million, representing a USD 7 million reduction. Furthermore, the lender has waived all accrued interest and converted the remaining balance into a zero-interest loan. These changes, including an extended repayment tenor, will substantially improve the subsidiary's liquidity and reduce the financial pressure on the parent company's corporate guarantee.
Key Highlights
Outstanding loan amount reduced by USD 7 million, from USD 12 million to USD 5 million
Complete waiver of accrued interest amounts by the Gates Foundation
Future interest rate set to 0% on the remaining USD 5 million loan balance
Revision of repayment schedule and extension of loan tenor to improve cash flow
Corporate guarantee by Hester India continues for the reduced loan amount
👀 What to Watch
Investors should view this as a significant positive development that de-leverages the consolidated balance sheet and improves the path to profitability for the African operations. Monitor the subsidiary's operational performance to see if these savings are reinvested into growth.
Hester Biosciences Q4 FY26 PAT Surges 174% Driven by Poultry Segment and Exceptional Gains
Hester Biosciences reported a strong performance for Q4 FY26, with standalone revenue growing 22% and PAT jumping 174% YoY. The Poultry Healthcare division was the primary growth engine, recording 41% growth in Q4, while the consolidated annual PAT doubled, partly aided by exceptional income from a stake sale in Texas Lifesciences. The company has successfully capitalized its new Fill-Finish and BSL-3 facilities and received licenses for the H9N2 Avian Influenza vaccine. Despite earlier delays in government tenders, the company executed the supply of 6.3 crore PPR vaccine doses in the final quarter.
Key Highlights
Standalone Q4 PAT increased by 174% YoY, while consolidated FY26 PAT grew by 100% to reach record levels.
Poultry Healthcare division revenue grew 41% in Q4 and 21% for the full financial year FY26.
Supplied 6.3 crore doses of PPR vaccine in Q4 FY26, signaling a recovery in the Animal Healthcare tender business.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, targeting the private commercial market.
Capitalized new Fill-Finish and BSL-3 facilities to enhance drug product capacity and operational efficiency.
👀 What to Watch
Investors should focus on the company's transition toward higher-margin biologicals and the scaling of the H9N2 vaccine. The successful capacity expansion and recovery in tender execution provide a positive outlook for FY27.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
Key Highlights
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.
Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.
Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.
Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.
Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 What to Watch
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
Key Highlights
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.
The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.
Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.
Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.
The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 What to Watch
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Reports FY26 Consolidated Revenue of ₹332.6 Cr; 35% Poultry Vaccine Market Share
Hester Biosciences reported a consolidated revenue of ₹332.60 crore for FY 2025-26, with a consolidated PAT of ₹28.83 crore. The company maintains a dominant position as India's second-largest poultry vaccine manufacturer with a 35% market share. Notably, standalone PAT was significantly higher at ₹52.10 crore, suggesting that international subsidiaries in Nepal and Africa are currently impacting overall group profitability. The company is strategically focusing on the Petcare segment and large-scale vaccine projects in Africa to drive future growth.
Key Highlights
Consolidated revenue reached ₹332.60 Cr in FY26, with Poultry Healthcare contributing 62% and Animal Healthcare 38%.
Standalone PAT stood at ₹52.10 Cr, while consolidated PAT was lower at ₹28.83 Cr due to subsidiary performance.
Maintains a 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine.
Total annual manufacturing capacity across India, Nepal, and Africa plants exceeds 11.3 billion doses.
Ongoing expansion into the Petcare division and the VITAL 2 project for ruminant vaccines in Kenya, Nigeria, and Tanzania.
👀 What to Watch
Investors should focus on the company's ability to improve the profitability of its African and Nepal subsidiaries to match its strong standalone performance. The dominant market share in poultry vaccines and entry into the high-margin Petcare segment are positive long-term indicators.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
Key Highlights
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.
Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.
Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.
Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 What to Watch
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
